Aeternum Health (AETN) Research & Development (2010 - 2019)

Aeternum Health has disclosed Research & Development across 10 years of filings, most recently posting -$592.0 for Q4 2019.

• In Q4 2019, Research & Development changed N/A year-over-year to -$592.0; the TTM figure through Nov 2019 stood at -$1180.0 (down 1915.38% YoY), while the FY2015 annual figure was $461.0, down 86.52% from the prior year.
• Research & Development declined to -$592.0 in Q4 2019, from -$588.0 in the prior quarter.
• Over the last five years, Research & Development for AETN reached as high as $2234.0 in Q2 2016 and fell as low as -$592.0 in Q4 2019.
• The 5-year median for Research & Development is $12.0 (2017), against an average of $112.38.
• Annual changes were most pronounced in 2015 — Research & Development sank 123.68% — and 2016, when it soared 276.09%.
• A 5-year view of Research & Development shows it stood at -$49.0 in 2015, then surged by 214.29% to $56.0 in 2016, then sank by 42.86% to $32.0 in 2017, then gained by 3.12% to $33.0 in 2018, then slumped by 1893.94% to -$592.0 in 2019.
• According to Business Quant data, Research & Development over the past three periods registered -$592.0, -$588.0, and $33.0 for Q4 2019, Q3 2019, and Q2 2018 respectively.